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Abstract
Background: Routinely collected health data (RCD) are increasingly used for randomized controlled trials (RCTs).
This can provide three major benefits: increasing value through better feasibility (reducing costs, time, and resources),
expanding the research agenda (performing trials for research questions otherwise not amenable to trials), and offering
novel design and data collection options (e.g., point-of-care trials and other designs directly embedded in routine care).
However, numerous hurdles and barriers must be considered pertaining to regulatory, ethical, and data aspects, as well
as the costs of setting up the RCD infrastructure. Methodological considerations may be different from those in
traditional RCTs: RCD are often collected by individuals not involved in the study and who are therefore blinded
to the allocation of trial participants. Another consideration is that RCD trials may lead to greater misclassification
biases or dilution effects, although these may be offset by randomization and larger sample sizes. Finally, valuable
insights into external validity may be provided when using RCD because it allows pragmatic trials to be performed.
Methods: We provide an overview of the promises, challenges, and potential barriers, methodological implications,
and research needs regarding RCD for RCTs.
Results: RCD have substantial potential for improving the conduct and reducing the costs of RCTs, but a multidisciplinary
approach is essential to address emerging practical barriers and methodological implications.
Conclusions: Future research should be directed toward such issues and specifically focus on data quality validation,
alternative research designs and how they affect outcome assessment, and aspects of reporting and transparency.
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Clinical epidemiology
Background
Routinely collected health data (RCD), such as electronic
health records (EHRs), registries, or administrative
claims data, are useful for randomized controlled trials
(RCTs), especially those whose aim is pragmatic. RCTs
embedded in routine data collection might be the next
disruptive clinical research technology [1]. However, nu-
merous fundamental questions have recently been raised
[1–8]. In this review, we summarize the promise and po-
tential barriers, followed by methodological implications
and research needs, for the better use of RCD for RCTs,
thus collating an overview of the current applicability
and promise of the use of RCD in clinical trials.
Potential value of RCD for RCTs
RCTs are often very expensive. Some trials are stopped
early because of failure to recruit; some fail to generate
useful evidence for clinical practice; and in some, the re-
sults are not disseminated at all. Various limitations of
RCTs are used as arguments to support observational
“real-world” RCD studies [9, 10]. We argue that some of
the limitations of RCTs are better addressed with RCD
within a randomized design, avoiding the problems of
confounding when assessing treatment effects (Table 1).
The use of RCD can replace or supplement some or all
procedures of traditional trials, and sometimes a blend
of routinely collected and actively collected data may be
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more feasible and useful. In Fig. 1, based on a modified
CONSORT (Consolidated Standards of Reporting Trials)
[11] trial flow diagram, we illustrate the roles of RCD
during the subsequent phases of a trial.
RCDs may make RCTs easier and more feasible by re-
ducing costs, time, and other resources. This might
mean larger RCTs for the same cost or RCTs in research
areas where high costs and insufficient funding previ-
ously precluded their conduct. Finally, even when cost
and resource limitations do not exist, RCD may foster
novel research activities, such as the use of registries for
rapid, consecutive trial enrollment [3, 4].
Value through better feasibility
Effective recruitment is necessary for a successful trial
[12]. Targeted screening strategies to identify eligible pa-
tients with routine data may lead to more efficient
recruitment. They may be used alone but also as a supple-
ment to traditional methods. Researchers can screen elec-
tronic databases and contact eligible patients or their
healthcare professionals, reducing costs associated with
recruitment during the delivery of healthcare, sometimes
for hefty fees [13]. Data-mining tools implemented in pre-
existing EHR systems can scan patient charts to identify
eligible patients automatically; electronic chart alerts can
then prompt the physician to suggest participation during
a routine clinical encounter or through contact via a letter
[14]. Registries of medical conditions, drug therapy, or de-
vices are especially valuable, particularly when patients
with rare diseases or other uncommon characteristics are
sought [15]. Registers of individuals interested in research
(see, e.g., www.registerforshare.org) that can be linked to
EHRs also support pretrial identification of potentially
eligible participants. Even more widely available than
registries, health insurance databases provide an extensive
sampling frame for patient recruitment, as well as a wealth
of outcome data [5].
All or some outcome data could be taken from RCD,
reducing the need for cumbersome follow-up visits, be-
spoke data collection, costly monitoring, and audits.
Building new infrastructures outside standard health-
care, training research staff, or purchasing additional
equipment are avoided. This may accelerate trial setup,
provide faster results, and also reduce trial costs signifi-
cantly. Site monitoring accounts for 9–14% of total trial
Table 1 Common limitations of randomized controlled trials and whether they can be amended by routinely collected health data
Limitations of
RCTs [10]
What using RCD for RCTs can offer Challenges Potential of RCD
to improve RCTs
Generalizability
and real-world
relevance
No specific data collection processes (follow-up visits,
measurements) outside routine care, avoiding artificial
situations
Random allocation of interventions may still require
some deviation from routine care processes
(e.g., obtaining informed consent).
Very high
Costs and
resources
No costs to the trial for data collection processes and
related activities (study site setup, study staff salary,
monitoring and auditing activities, training costs)
Potential costs for obtaining the RCD (if the
collecting entity does not provide it for free;
e.g., data brokers); additional costs for data
management, processing, merging, cleaning,
and so forth
Very high
Specific conditions/
subgroup
effects
Larger sample sizes that are less influenced by resource
constraints and feasibility issues may provide sufficient
power for evaluating subgroups.
More opportunities for exploratory analyses with
spurious findings
High
Late outcomes RCD can provide long-term outcome data without
actively following patients and often reducing the
number of patients lost to follow-up
Patients moving away from RCD infrastructure will
be lost and may still require active contact, highly
dependent on RCD infrastructure
High
Speed No cumbersome outcome ascertainment (follow-up
contacts, data recording and collection) and no need for
setting up the data collection infrastructure, thus results
can be obtained faster
Management, processing, merging, and “cleaning”
of large datasets may be time-consuming.
Reporting of specific adverse events may be
delayed.
High to moderate
Conflicts of
interest/
sponsorship
bias
Collection of RCD is more objective and less easily
manipulated to obtain a desired result.
Data may still be analyzed and reported
nonobjectively to convey preferred conclusions.
Moderate
Understudied
healthcare
questions
Providing information on routine care allows researchers
to address understudied healthcare questions because
more resources are spared or different outcomes are
collected.
Not all desired endpoints might be available;
funding may not be the sole barrier
Moderate
Regulations Obtaining approval for intervention imposes several
bureaucratic loopholes; RCD are already available and
might require different ethical clearance.
RCD still require approval in terms of data protection
and confidentiality.
Moderate
Rare or
uncommon
conditions
Recruiting an appropriate sample size may be hard with
rare diseases; larger samples with RCD and easier EHR or
registry recruitment can reduce these difficulties.
Only possible if RCD resources are extensive, highly
dependent on RCD infrastructure
Moderate
Abbreviations: EHR Electronic health record, RCD Routinely collected health data, RCT Randomized controlled trial
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costs [16]. In addition, administrative burden and staff
costs account for 15–22% of the traditional total trial ex-
penditures [16]. Most issues detected by monitoring are
due to poor source documentation [17] (i.e., a data point
is not inserted in the trial master file or a consent form
is not properly filled).
Value through expanded research agenda
Research questions not otherwise amenable to trials (e.g.,
in rare diseases) might be answerable with RCD. For ex-
ample, local and national registers of people with myo-
tonic dystrophy played an important role in the successful
recruitment strategy of the OPTIMISTIC trial [18].
Using RCD may help to address some traditional im-
balances in the evidence landscape and reduce trad-
itional research agenda biases. Treatments that are
typically not championed by commercial interests, such
as exercise or physical therapy, speech therapy, psycho-
therapy, or surgeries, are less supported by randomized
evidence than drugs or devices. Any cost reduction
could facilitate trials for interventions that typically
strongly depend on public funding structures and
noncommercial research support. By saving resources
elsewhere, RCD-based trial research may broaden
therapeutic options or even reveal better treatments.
For drug therapies, the use of RCD may allow inde-
pendent realization of notoriously lacking head-to-head
comparisons and evaluation of “blockbuster drugs” in
pragmatic megatrials [19]. Those drugs are used by mil-
lions of individuals, but RCT evidence to support them
comes only from several hundred or a few thousand pa-
tients, often without patient-relevant outcomes and with
strict eligibility criteria. The possibility of long-term
outcome assessments makes RCD an excellent tool for
Fig. 1 The role of routinely collected health data (RCD) in randomized controlled trials in various phases of a clinical trial (based on the Consolidated
Standards of Reporting Trials [CONSORT] flow diagram [11]). (1) During enrollment, RCD sources can be screened retrospectively for eligible patients,
but they can also be used prospectively as targeted screening and recruitment tools. (2) Informed consent could be given both for data use and for
trial participation, so that when patients decline to participate in the randomized component of the trial, their usual care can still be followed. (3)
Allocation can be facilitated by RCD through point-of-care randomization. Patients who are not allocated to an intervention but select care on the
basis of personal and clinical preferences can be observed with RCD. (4) During the follow-up phase, RCD allows patients who would otherwise be lost
to follow-up to be tracked, and thus less missing data may be encountered. (5) Long-term follow-up, such as in registries, may be possible with RCD
even after formal completion of the primary study phase. (6) RCD allows analysis of both nonrandomized and randomized patients and direct
supplementation of information to the randomized part of the trial
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postmarketing surveillance. Public funders may also have
more chances to initiate independent research, increas-
ing transparency and potentially directly addressing
areas with suspected publication or reporting biases.
The conducted RCTs may better reflect the true health-
care needs and avoid “cost and convenience” biases
resulting from choosing a research question on the basis
of what is affordable.
Whereas many outcomes that are traditionally of
interest in clinical research, including biomarkers and
patient-reported outcomes, are not included in most
RCD sources, RCD typically include outcomes that are
not included in many traditional RCTs (return to work,
need for home nursing, sick days, disability, and major
events such as cancer diagnoses or accidents). Imple-
menting RCTs at the point of care, with randomization
occurring directly in EHR platforms, might lead to RCTs
having more generalizable results that assess more
patient-relevant and clinically relevant outcomes [6, 20,
21]. Such RCTs could provide insight in situations where
surrogate or combined outcomes are often used for con-
venience or safety reasons but are considered subpar
[22, 23]. RCD-based RCTs often have more patient- and
clinician-relevant outcomes that can inform comparative
effectiveness research and guide clinical decision-making
rather than provide information for mechanistic or
proof-of-concept studies [21]. With increasing incorpor-
ation of patient-reported outcomes and even mechanis-
tic data (e.g., genomics) in EHR in routine care [24], this
gap may eventually be removed. Indeed, increasing the
research use of RCD may lead to changes in the out-
comes collected in routine data, a process that needs to
maintain a careful balance between workload and utility.
Value through improved design and data collection options
Instead of inviting a patient for a repeated measurement
or calling his/her healthcare provider for the patient’s
clinical information, the researcher can access the RCD
database and extract it autonomously, which avoids dis-
rupting the usual care environment and without coming
to the attention of the patient or care provider or requir-
ing additional work from either. By reducing the need to
affect the flow of routine care and the need to contact
patients and care providers, such as by artificial blinding
and outcome assessment procedures, observer bias (i.e.,
Hawthorne effect) is minimized. This may be especially
true for behavioral interventions [25].
Administrative databases offer a wider array of vari-
ables of interest to use in an RCT, including social fac-
tors, unemployment or disability status, or healthcare
use. For example, an insurance claims database could be
queried automatically at admission to identify individ-
uals frequently visiting an emergency department to
target them for a discharge-planning intervention.
Retrospectively linking RCT databases with RCD sup-
ports data collection after regulatory approval is given
for a drug or device. For example, data from large
approval trials could be linked with cancer registries for
evaluation of postapproval safety concerns, or very long-
term trial outcomes could be collected from registries,
as was done in the West of Scotland Coronary
Prevention Study [26].
Practical barriers to using RCD for RCTs
Greater use of RCD in RCTs is challenging. When using
RCD to overcome some of the limitations of traditional
RCTs, several additional barriers may occur and can be
classified into four principal domains: data, regulatory
and ethical aspects, costs, and novelty (Table 2).
Data
Even when the RCD necessary to answer a research
question is available, it may be difficult to locate and ac-
cess. The data owner may not be easy to contact, may
not be willing to provide or share the data, or may not
be able to provide it in a form that one may need to
conduct an RCT, such as aggregated data being offered
when individual patient data are what is needed.
The datasets may be very large, requiring a substantial
information technology (IT) system, including human
resources, hardware, and software to sort through and
organize the data in such a way that it can then be ana-
lyzed. Connecting or linking to a research database with
a system that is either continuously collecting the data
(such as an EHR) or to another database (such as insur-
ance claims database) requires significant planning and
software development.
A few RCD variables and some RCD source types may
be more accurate and better validated than others. Each
variable for each source has variability in its accuracy
that makes it difficult to make a general accuracy judg-
ment. Hence, different EHRs or registries may have dif-
ferent data quality (quantity of missing data as well as
actual correctness of the data), but the major obstacle
remains the variability within the same source [2, 7].
However, a validation of the RCD source by manually
checking a sample of the dataset before each trial would
become cumbersome and may offset the advantages of
RCD use in the first place. Even with randomization, the
quality of the data may sometimes still depend on the
assigned intervention and thus may be different between
the comparison groups.
All in all, each research question, or even each outcome
estimate, should be carefully examined, paired with the
specific RCD source and variables used, to establish
whether such elements were appropriate and what degree
of confidence can be placed in such outcome assessments.
A population registry based on a unique identifier that
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every individual receives at birth and has been established
for many years with considerable resources for quality as-
surance (e.g., in Denmark [27]) is likely more accurate
than EHRs of a small commercial practice. Systematic val-
idation standards clearly describing and comparing valid-
ity and accuracy of codes and algorithms used for
identification of patients, conditions, treatments, or out-
comes are currently not universally established for RCD.
Regulatory and ethical aspects
Core ethical principles for clinical research include in-
formed consent, independent ethics review, confidentiality,
or risk management (e.g., audit, serious adverse event
reporting). Although the principles themselves remain the
same, differences exist in the way in which they can and
should be applied in research with RCD. Some ethical is-
sues, such as confidentiality, can become more significant,
whereas others, such as consent and audit, might be sim-
plified. In particular, when variations of usual care are ex-
plored, privacy-related issues typically dominate ethical
assessments. Recent guidelines [28] and reports [29] ad-
dressing research with collected and linked health data
highlight the opportunities and challenges of innovative
and feasible concepts for consent and further oversight.
Table 2 Barriers in the use of routinely collected health data for randomized controlled trials and options for improvement
General barriers or issues Pressing questions Possible solutions, actions and additional comments
Data
▪ Availability
▪ Management
▪ Linkage
▪ Accuracy
▪ Validity
▪ Is the desired outcome variable or RCD source
available?
▪ Will it be possible to achieve the same
data quality and accuracy with
RCD as in traditional trials?
▪ Is the data linkage and management feasible in
institutions with limited IT infrastructure?
▪ A central register of databases available for clinical
trial research would be helpful, ideally with details
about data quality.
▪ Establish core outcomes and structured outcome
assessments in routine care
▪ Create RCD trial guidelines and RCD source
validation guidelines to help standardize their use
and reduce sources of bias or uncertainty
▪ Increase IT presence (particularly data analysts) to
health research teams
▪ The more RCD is sought out and used in research,
the greater is its availability and differentiation.
Regulatory and ethics
▪ Collecting and obtaining the data
▪ Using and sharing the data
▪ What type of release must be given by the patients
before their data can be collected or shared?
▪ Is it ethical to use RCD without asking for their
permission, even if their data are anonymized?
▪ Can this data be considered of value and morally
be sold?
▪ How are concerns about privacy and informed
consent approached (particularly in the context of
population-wide trials or Zelen designs)?
▪ Are data safety standards applied to RCD just as
strictly as they are to traditional actively collected
data?
▪ Who is responsible for the safety of the data?
▪ Ethical guidelines specifically regarding the
collection and dissemination of RCD should be
developed.
▪ Ethics and approval committees should deepen
their knowledge of these novel ethical challenges.
▪ Whereas personal data are collected daily from
many sources (e.g., phone use), collection, storage,
and dissemination of data related to health require
more definite ethical oversight and greater
transparency to the general public.
▪ After safety issues are defined, researchers and
stakeholders must ensure that data are safely
handled, with full transparency of access.
Costs
▪ Obtaining the data
▪ Managing the data
▪ Will data collectors (e.g. health insurers) share their
data? Freely or at a cost?
▪ Is a constant increase in the generation of routine
data really reducing the overall trial costs if the same
institution collected the data in the first place?
▪ When is the use of RCD cost-effective?
▪ The financial worth of health data is not defined or
explored; empirical data are necessary to determine
the cost of both producing and maintaining health
data
▪ Health data are already legally sold to many
industries, and regulations/legislation must catch up
with this aspect.
Novelty
▪ Bureaucratic obstacles
▪ Unawareness
▪ Training to generate, collect, prepare,
manage and analyze RCD for trials
▪ Will approval committees understand the
implications of using RCD sources for clinical trials?
▪ What are the challenges that can be expected
bureaucratically because most submission templates
do not assume the use of RCD and absence of
patient contact?
▪ Are data anonymization techniques clear?
▪ What training is required to qualify individuals who
generate, collect, prepare, and manage RCD for
clinical trial research?
▪ Develop, in collaboration with approval committees,
RCD-specific templates and submission forms,
especially in such studies where no patient contact
is foreseen and therefore speedy approval is desired.
▪ Educate regarding data anonymization and
confidentiality risks
▪ Include the concept of using RCD for RCT in clinical
research education and teaching
▪ Create and use reporting guidance specifically for
RCD-RCTs
IT Information technology, RCD Routinely collected health data, RCT Randomized controlled trial
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Whereas some argue that even a “no-consent” model
whereby patients would be unaware of participating in an
RCT could be in line with ethical principles and current
law [30], others advocate for the so-called integrated verbal
consent models that incorporate a notification of
randomization into the usual clinical discussion between
physician and patient [8]. Although in recent public sur-
veys the majority of the community still preferred written
consent prior to participating in pragmatic RCTs [31],
most would also accept verbal consent or general notifica-
tion if written consent would make the research too diffi-
cult to carry out [32].
Templates for broad consent texts have already been
developed and implemented for research with human
biospecimens and might be applied in a modified and
simplified version for research with RCD [33, 34].
Consistent with international ethical guidelines, ethics
review committees may also waive the requirement for
informed consent when research participation involves
no more than minimal risk and requiring informed con-
sent would make the study impracticable.
When using high-dimension datasets, effective anon-
ymization is often quite difficult [35]. With a larger
sample size, anonymity may be easier to achieve,
whereas more detailed data may allow easier breach.
The most appropriate data protection model, therefore,
needs to be tailored to the individual RCD project. In
general, research staff with access to confidential records
must be adequately trained, and a liability protection
considering patient privacy and potential data breech
should be considered.
At a policy level, public and patient involvement builds
another cornerstone for long-term public trust in re-
search with RCD, especially when such research includes
consent waivers or broad consent [29, 36]. Public inter-
ests, however, reflect not only the protection of privacy
but also research with RCD that can improve public
health. Overall, the uses of RCD, in particular its collec-
tion, storage, and dissemination, raise novel ethical con-
siderations that may require further development of
regulations to ensure adequate protections but without
unduly constraining the potential benefits of greater
research use of RCD.
Costs
Setting up infrastructures to implement use of RCD for
clinical research may be associated with enormous over-
head costs. Specific investments may be needed before
starting such research. Although the costs related to
maintaining the RCD source (e.g., insurance claims data-
bases) may not rely on the researcher, this should be
considered in institutions where both clinical practice
and research take place, such as in university hospitals.
It may become common practice to charge for the
release of RCD once it becomes more widely used.
Alternative models involving supported access to RCD
are also possible; Scotland’s electronic Data Research
and Innovation Service provides access and support and
publishes charging structures [37]. Even if data are
shared for free, costs are associated with finding the
correct data, negotiating its acquisition or access, and
transferring or linking such data to the trial database.
Specifically trained personnel and specific resources may
be required to manage and link the data, as well as to
ensure privacy and data protection. Once a trial database
is established and linked to the RCD source, mainten-
ance costs may be incurred. Nonetheless, it may be
argued that many of these investments will be offset by
later cost savings when RCD is used in trials (e.g., by
making some monitoring activities obsolete). The real
challenge will arise when costs and savings are borne
and won by different organizations.
Novelty
The novelty of using RCD for trials may itself be a bar-
rier. Established structures, such as templates for ethical
approval or grant proposals, are often not yet designed
to apply to this kind of research.
Guidelines for use and handling of RCD often stem
from nonexperimental research with other foci. For
example, on one hand, the most widely used report-
ing guideline for this type of data was developed for
observational RCD analyses (the REporting of studies
Conducted using Observational Routinely collected
health Data [RECORD] statement [38]), but there is
no reporting guideline addressing the specific issues
of RCD in the context of RCTs. On the other hand,
there are initiatives to provide guidance, such as the
recently drafted guidance for industry on approval of
medical devices by the U.S. Food and Drug Adminis-
tration [39].
Furthermore, the novelty of the technology itself
will require additional training and data science staff
necessary to implement RCD-RCTs embedded in rou-
tine care. Although RCD-RCTs may reduce the costs
associated with training research staff for patient
recruitment or outcome ascertainment, any savings
may be offset by new expenses for training those who
generate and collect the RCD so that the data can be
used for research and for training researchers to
prepare, manage, and analyze this data within a clin-
ical trial framework.
Methodological implications
In addition to general barriers to using RCD in clinical
trial research, novel methodological problems and
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potential biases may be introduced. However, use of
RCD may also reduce and preemptively avoid some
internal validity biases and provide valuable insights into
external validity by showing potential differences be-
tween included patients and/or nonincluded but eligible
individuals.
RCD-based research obviously requires reasonable
data quality, but this holds for both randomized and
observational research using RCD. Data quality issues,
including misclassifications, are much less of a problem
with randomization, however, because this typically rules
out the possibility that the explored intervention is
related to data quality. This is in sharp contrast to obser-
vational studies, where determination of exposures may
actually be strongly associated with data quality and in-
crease risks of misclassification and detection biases.
However, even in a trial, it may be problematic when the
measurement of outcomes is associated with the allo-
cated intervention. Bias might occur, for example, when
one study intervention leads to more contact with
healthcare professionals who collect the routine
outcome data in a different way (e.g., by using more sen-
sitive diagnostic procedures, by coding the data differ-
ently, or by using different time schedules for
examinations). Possible solutions include standardized
documentation of core outcomes (e.g., through a
structured assessment of all patients at hospital
discharge) and training of healthcare professionals to
perform standardized data entry. Efforts at stan-
dardization may escalate cost, however, and diminish
the advantages related to the ease and low cost of
using the RCD.
Not only quality but also timeliness deserves attention,
because timely assessment of safety issues may be chal-
lenging when a specific adverse event data collection
mechanism is not in place as in traditional RCTs [7].
Because routine data are typically collected only at the
time of clinical encounter and then need to be proc-
essed, registered in the database, and made accessible to
the researcher, there may be substantial delay between
occurrence of adverse events and recognition by the
researchers. Combining routine data with active collec-
tion in a hybrid approach may help, for example, by per-
forming telephone checks to randomized patients to
seek adverse event information [7]. Active collection,
however, requires substantial resources.
However, outcome data collection in RCD-RCTs may
have advantages because it is often formally blinded, as
in any traditional trial, with blinded endpoint assess-
ment. Then, and when outcome data collection is stan-
dardized and unrelated to the intervention, any
misclassification would be completely at random and
only introducing noise and decreasing precision of out-
come estimates.
Dilution of effects due to imprecision and misclassifi-
cation may gain particular importance for noninferiority
questions or evaluation of some adverse events, which
may be less adequately addressed with RCD of uncertain
data quality. One potential solution is to increase sample
size to account for the increased noise that RCD brings.
In principle, at least, easy provision of larger sample
sizes is one of the key advantages of RCD-RCTs, so mak-
ing this a routine requirement ought not to be a sub-
stantive barrier.
Data completeness of RCD-RCTs is not necessarily a
problem; actually, sometimes it is quite the opposite,
with levels of completeness that are rare in traditional
trials. For example, the TASTE trial (Thrombus aspir-
ation during ST-segment Elevation myocardial infarc-
tion) [40], embedded within the Swedish Coronary
Angiography and Angioplasty Registry, evaluated more
than 7244 participants with zero patients lost to follow-
up. Internal validity may be compromised when mecha-
nisms lead to loss to follow-up and missing data are not
completely at random. RCD may shed light on this,
because often there are still data collected for those
patients even after dropout. RCD may in fact provide
excellent information on whether a treatment is well-
tolerated and by whom it is not, as well as on the
intervention’s side effects or drawbacks. Furthermore,
one can examine the outcomes of patients who
deviated from the original treatment plan, such as
patients who discontinued taking the allocated drug
and had surgery instead. With an expanded RCD
source such as a national EHR system, outcomes can
be available even for those patients who were lost to
follow-up. However, this is possible only when the
RCD data sources are accurate and extensive enough
(such as in Sweden [41] or Canada [42]) to track
withdrawn patients.
Next steps and research needs
Careful evaluation of data accuracy, including validation
and clarification of algorithms, appears to be one of the
most important issues. Other important questions may
be asked. Are outcome estimates different when mea-
sured in RCD-RCTs compared with RCTs with trad-
itional active data collection? If so, are they source-
specific, or do they depend on the type of outcome?
How can users of trial research determine if the data are
sufficiently accurate? A central register listing routine
datasets available for trial research, including informa-
tion on data quality and validity, would be helpful. A
general standardization of routine data collection to en-
sure that it is useful not only for patient care and admin-
istration but also for research would be desirable.
Employment of electronic algorithms that could be used
to automatically perform validation checks (either at the
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moment of data entry or as random, systematic, and
regular checks) might also be helpful [7].
Other questions that require exploration are related to
patient recruitment and consent. Does pragmatism affect
the estimates of treatment effects? Are different consent
models needed? Are Zelen trials done without obtaining
consent from each and every participant, giving results
similar to those of other trials that require consent from
everyone? And how can randomization become a stand-
ard usual care procedure despite short appointments
and constrained resources in clinical care?
Development of guidelines for review, conduct, and
reporting of trials using RCD may be helpful. Systematic
reviewers, health technology assessors, and regulators
and other users of this research may need novel tools
and some training to assess the quality and risk of bias
of such evidence.
Conclusion
RCD have substantial potential for improving the
conduct and reducing the costs of RCTs. Future re-
search should specifically focus on data quality valid-
ation, alternative research designs and how they affect
outcome assessment, and aspects of reporting and
transparency.Many of these issues will require multi-
disciplinary research efforts and a large international
research initiative on RCD for RCTs. This will allow
researchers to exchange, collaborate, and learn but
would require support by some structured funding
and resources. Overall, better understanding of how
to make the best use of RCD for RCTs is needed.
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